Search Results

You are looking at 21 - 30 of 865 items for :

  • Refine by Access: All x
Clear All
Full access

Updates to the Management of Patients With Relapsed or Refractory Indolent Follicular and Marginal Zone Lymphomas

Presented by: Ann S. LaCasce and Ariela Noy

lymphomas (MZLs). Although the diseases share similarities, FL and MZL have distinct biological differences that affect presentation and treatment. Dr. LaCasce summarized the data from clinical trials on the use of targeted therapies for relapsed or

Full access

Update on CAR T-Cell Therapies for Relapsed/Refractory B-Cell Lymphomas

Presented by: Stephen J. Schuster

CD19-directed CAR T-cell therapies for relapsed/refractory B-cell lymphomas. “Given the unprecedented bench-to-bedside clinical success, research and development aimed at refining our existing immunotherapies is proceeding at a very rapid pace,” said

Full access

Optimizing Treatment of Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Presented by: Anthony Mato

The advent of targeted agents for relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) has led to significant improvements in overall survival (OS), progression-free survival (PFS), and quality of life

Full access

Biochemical Relapse After Primary Treatment for Prostate Cancer: Studies on Natural History and Therapeutic Considerations

Eli Rosenbaum, Alan Partin, and Mario A. Eisenberger

PSA era . Int J Radiat Oncol Biol Phys 2003 ; 57 : 915 – 928 . 5 Sylvester JE Blasko JC Grimm PD . Ten-year biochemical relapse-free survival after external beam radiation and brachytherapy for localized prostate cancer: the Seattle

Full access

Updates in the Management of CLL/SLL: Management of Relapsed/Refractory Disease and the Role of Minimal Residual Disease

Presented by: Jennifer R. Brown

The landscape of relapsed chronic lymphocytic leukemia (CLL) has changed dramatically over the past few years primarily due to changes in the frontline setting. During the NCCN 2021 Virtual Annual Conference, Jennifer R. Brown, MD, PhD, Director

Full access

An Unusual Presentation of Chronic Myelogenous Leukemia: A Review of Isolated Central Nervous System Relapse

Scott M. Lindhorst, Richard D. Lopez, and Ronald D. Sanders

presented with an isolated central nervous system (CNS) relapse after standard imatinib therapy with good response. Further treatment options, and monitoring of disease response, are discussed. Case Report A 24-year-old otherwise healthy Caucasian

Full access

Review of Late Complications of Treatment and Late Relapse in Testicular Cancer

Eleni Efstathiou and Christopher J. Logothetis

plasma levels and nephrotoxicity . J Clin Oncol 1987 ; 5 : 304 – 309 . 95. Baniel J Foster RS Gonin R . Late relapse of testicular cancer . J Clin Oncol 1995 ; 13 : 1170 – 1176 . 96. George DW Foster RS Hromas RA . Update on

Full access

Relapsed/Refractory Diffuse Large B-Cell Lymphoma and Mantle Cell Lymphoma: Is It Time to Consider CAR-T for All?

Presented by: Andrew D. Zelenetz

CAR T cells continue to show impressive activity in relapsed/refractory non-Hodgkin lymphoma, with durable complete responses in a significant percentage of patients with chemorefractory disease. According to Andrew D. Zelenetz, MD, PhD, Medical

Full access

Post-Chemoradiation Surgical Pathology Stage Can Customize the Surveillance Strategy in Patients With Esophageal Adenocarcinoma

Takashi Taketa, Kazuki Sudo, Arlene M. Correa, Roopma Wadhwa, Hironori Shiozaki, Elena Elimova, Maria-Claudia Campagna, Mariela A. Blum, Heath D. Skinner, Ritsuko U. Komaki, Jeffrey H. Lee, Manoop S. Bhutani, Brian R. Weston, David C. Rice, Stephen G. Swisher, Dipen M. Maru, Wayne L. Hofstetter, and Jaffer A. Ajani

relapses are common. 7 - 10 After TMT, most patients undergo surveillance for at least 5 years; however, the surveillance recommendations vary considerably and are often empiric in nature. 6 , 10 Relapses seem to be related to the sensitivity of the

Full access

Challenges in the Treatment of Newly Diagnosed and Recurrent Primary Central Nervous System Lymphoma

Matthias Holdhoff, Maciej M. Mrugala, Christian Grommes, Thomas J. Kaley, Lode J. Swinnen, Carlos Perez-Heydrich, and Lakshmi Nayak

-MTX) backbone, have demonstrated efficacy in the treatment of newly diagnosed and relapsed or refractory (R/R) PCNSL, but currently there is no consensus on the optimal treatment of these patients. Very few prospective randomized controlled studies have been